These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 19716365

  • 41. HIV-Tat-mediated Bcl-XL delivery protects retinal ganglion cells during experimental autoimmune optic neuritis.
    Diem R, Taheri N, Dietz GP, Kuhnert A, Maier K, Sättler MB, Gadjanski I, Merkler D, Bähr M.
    Neurobiol Dis; 2005 Nov; 20(2):218-26. PubMed ID: 16242630
    [Abstract] [Full Text] [Related]

  • 42. Macrophages and neurodegeneration.
    Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD.
    Brain Res Brain Res Rev; 2005 Apr; 48(2):185-95. PubMed ID: 15850657
    [Abstract] [Full Text] [Related]

  • 43. Use of stem cells for the treatment of multiple sclerosis.
    Karussis D, Kassis I.
    Expert Rev Neurother; 2007 Sep; 7(9):1189-201. PubMed ID: 17868017
    [Abstract] [Full Text] [Related]

  • 44. Erythropoietin as a neuroprotective agent in traumatic brain injury Review.
    Mammis A, McIntosh TK, Maniker AH.
    Surg Neurol; 2009 May; 71(5):527-31; discussion 531. PubMed ID: 18789503
    [Abstract] [Full Text] [Related]

  • 45. Knowns and unknowns in the future of multiple sclerosis treatment.
    Stüve O.
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
    [Abstract] [Full Text] [Related]

  • 46. Disease-modifying drugs and Parkinson's disease.
    Allain H, Bentué-Ferrer D, Akwa Y.
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [Abstract] [Full Text] [Related]

  • 47. I can't get no satisfaction: still no neuroprotection for Parkinson disease.
    Ahlskog JE.
    Neurology; 2007 Oct 09; 69(15):1476-7. PubMed ID: 17923609
    [No Abstract] [Full Text] [Related]

  • 48. Neuroprotective agents: cannabinoids.
    Sánchez AJ, García-Merino A.
    Clin Immunol; 2012 Jan 09; 142(1):57-67. PubMed ID: 21420365
    [Abstract] [Full Text] [Related]

  • 49. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system.
    't Hart BA, Amor S.
    Curr Opin Neurol; 2003 Jun 09; 16(3):375-83. PubMed ID: 12858076
    [Abstract] [Full Text] [Related]

  • 50. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.
    Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK.
    Glia; 2009 Jan 15; 57(2):182-93. PubMed ID: 18720408
    [Abstract] [Full Text] [Related]

  • 51. Immune-mediated neurodegeneration and neuroprotection in MS.
    Giuliani F, Yong VW.
    Int MS J; 2003 Dec 15; 10(4):122-30. PubMed ID: 14977489
    [Abstract] [Full Text] [Related]

  • 52. Critical appraisal of animal models of multiple sclerosis.
    Baker D, Gerritsen W, Rundle J, Amor S.
    Mult Scler; 2011 Jun 15; 17(6):647-57. PubMed ID: 21372117
    [Abstract] [Full Text] [Related]

  • 53. [Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis].
    Moreno B, Espejo C, Mestre L, Suardiaz M, Clemente D, de Castro F, Fernández-Fernández Ó, Montalban X, Villoslada P, Guaza C, Spanish Network for MS.
    Rev Neurol; 2012 Jan 16; 54(2):114-24. PubMed ID: 22234570
    [Abstract] [Full Text] [Related]

  • 54. Axonal protection using flecainide in experimental autoimmune encephalomyelitis.
    Bechtold DA, Kapoor R, Smith KJ.
    Ann Neurol; 2004 May 16; 55(5):607-16. PubMed ID: 15122700
    [Abstract] [Full Text] [Related]

  • 55. Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender.
    Kipp M, Amor S, Krauth R, Beyer C.
    Front Neuroendocrinol; 2012 Jan 16; 33(1):1-16. PubMed ID: 22289667
    [Abstract] [Full Text] [Related]

  • 56. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
    Neuhaus O, Archelos JJ, Hartung HP.
    Trends Pharmacol Sci; 2003 Mar 16; 24(3):131-8. PubMed ID: 12628358
    [Abstract] [Full Text] [Related]

  • 57. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis.
    Rieckmann P, Mäurer M.
    Curr Opin Neurol; 2002 Jun 16; 15(3):361-70. PubMed ID: 12045738
    [Abstract] [Full Text] [Related]

  • 58. Ibudilast for the treatment of multiple sclerosis.
    Goodman AD, Gyang T, Smith AD.
    Expert Opin Investig Drugs; 2016 Oct 16; 25(10):1231-7. PubMed ID: 27501293
    [Abstract] [Full Text] [Related]

  • 59. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
    Rottlaender A, Kuerten S.
    Int J Mol Sci; 2015 Jul 01; 16(7):14850-65. PubMed ID: 26140377
    [Abstract] [Full Text] [Related]

  • 60. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.
    Friese MA, Schattling B, Fugger L.
    Nat Rev Neurol; 2014 Apr 01; 10(4):225-38. PubMed ID: 24638138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.